FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model

被引:160
作者
Grundler, R
Miething, C
Thiede, C
Peschel, C
Duyster, J
机构
[1] Tech Univ Munich, Dept Internal Med 3, Lab Lukemogenesis, D-81675 Munich, Germany
[2] Tech Univ Dresden, Univ Klin Carl Gustav Carus, Med Klin & Poliklin 1, D-8027 Dresden, Germany
关键词
D O I
10.1182/blood-2004-11-4430
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Activating mutations of the Fms-like tyrosine kinase 3 (FLT3) receptor are the most common genetic alteration in acute myeloid leukemia (AML). Two distinct groups of FLT3 mutations are found: internal tandem duplications (ITDs) of the juxtamembrane region and point mutations within the tyrosine kinase domain (TKD). Recently, point mutations within the activation loop of FLT3 have also been described in childhood acute lymphoblastic leukemia (ALL). FLT3-ITD has been shown to induce a myeloproliferative syndrome in a murine bone marrow transplantation model. The phenotype of FLT3-TKD in mice has not yet been investigated. We transduced murine bone marrow with retrovirus-expressing FLT3-TKD mutants or FLT3-ITD and transplanted these cells into lethally irradiated mice. Mice that received a transplant of FLT3-ITD developed an oligoclonal myeloproliferative disease as previously described. In contrast, FLT3-TKD mutants induced an oligoclonal lymphold disorder with longer latency and distinct hematologic manifestations: importantly, induction of the lymphoid phenotype was not due to a low number of transplanted cells. The lymphoid manifestation and longer latency of FLT3-TKD compared with FLT3-ITD mutants together with the lack of influence of FLT3-TKD mutations on the clinical outcome of patients with AML suggest differences in cell signaling between FLT3TKD mutants and FLT3-ITDs. Indeed strong signal transducers and activators of transcription 5 (STAT5) activation could only be demonstrated for FLT3-ITDs. (c) 2005 by The American Society of Hematology.
引用
收藏
页码:4792 / 4799
页数:8
相关论文
共 42 条
[1]   Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia [J].
Abu-Duhier, FM ;
Goodeve, AC ;
Wilson, GA ;
Care, RS ;
Peake, IR ;
Reilly, JT .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) :983-988
[2]   FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group [J].
Abu-Duhier, FM ;
Goodeve, AC ;
Wilson, GA ;
Gari, MA ;
Peake, IR ;
Rees, DC ;
Vandenberghe, EA ;
Winship, PR ;
Reilly, JT .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) :190-195
[3]   Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification [J].
Armstrong, SA ;
Kung, AL ;
Mabon, ME ;
Silverman, LB ;
Stam, RW ;
Den Boer, ML ;
Pieters, R ;
Kersey, JH ;
Sallan, SE ;
Fletcher, JA ;
Golub, TR ;
Griffin, JD ;
Korsmeyer, SJ .
CANCER CELL, 2003, 3 (02) :173-183
[4]   FLT3 mutations in childhood acute lymphoblastic leukemia [J].
Armstrong, SA ;
Mabon, ME ;
Silverman, LB ;
Li, AH ;
Gribben, JG ;
Fox, EA ;
Sallan, SE ;
Korsmeyer, SJ .
BLOOD, 2004, 103 (09) :3544-3546
[5]   FLT3 Inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer [J].
Brown, P ;
Small, D .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (05) :707-721
[6]   Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm [J].
Fröhling, S ;
Schlenk, RF ;
Breitruck, J ;
Benner, A ;
Kreitmeier, S ;
Tobis, K ;
Döhner, H ;
Döhner, K .
BLOOD, 2002, 100 (13) :4372-4380
[7]  
Gilliland DG, 2003, BLOOD, V102, p107A
[8]   The roles of FLT3 in hematopoiesis and leukemia [J].
Gilliland, DG ;
Griffin, JD .
BLOOD, 2002, 100 (05) :1532-1542
[9]   Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor [J].
Grundler, R ;
Thiede, C ;
Miething, C ;
Steudel, C ;
Peschel, C ;
Duyster, J .
BLOOD, 2003, 102 (02) :646-651
[10]   Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines [J].
Hayakawa, F ;
Towatari, M ;
Kiyoi, H ;
Tanimoto, M ;
Kitamura, T ;
Saito, H ;
Naoe, T .
ONCOGENE, 2000, 19 (05) :624-631